Summary Background The Memorial Sloan Kettering Cancer Center (MSKCC) risk model is
an established prognostic tool for metastatic renal-cell carcinoma that integrates clinical and …

The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized
over the past two decades, bringing forth an era in which more than a dozen therapeutic …

Summary Background The International Metastatic Renal-Cell Carcinoma Database
Consortium model offers prognostic information for patients with metastatic renal-cell …

Background Identification of high-risk localised renal cell carcinoma is key for the selection
of patients for adjuvant treatment who are at truly higher risk of reccurrence. We developed a …

Purpose Following curative treatment for localised renal cell carcinoma (RCC), up to 30% of
patients develop tumour recurrence. Prognostic scores are essential to guide individualised …

Background Metastatic renal cell carcinoma (RCC) patients are commonly treated with
vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin …

Background Improved markers for predicting recurrence are needed to stratify patients with
localised (stage I–III) renal cell carcinoma after surgery for selection of adjuvant therapy. We …

Background Renal cell carcinoma (RCC) is a heterogeneous disease comprising
histologically defined subtypes. For therapy selection, precise subtype identification and …

Background Risk stratification for localized renal cell carcinoma (RCC) relies heavily on
retrospective models, limiting their generalizability to contemporary cohorts. Objective To …

The availability of agents directly targeting tumorigenic and angiogenic pathways has
significantly improved the outcomes of patients with advanced renal cell carcinoma (RCC) in …